Filtered By:
Source: International Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance. This is page number 9.
Order by Relevance | Date
Total 388 results found since Jan 2013.
Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial
Conclusions: In patients with AF, apixaban more often prevented stroke or systemic embolism and death and caused less bleeding than warfarin, regardless of the presence of prior CAD. Given the common occurrence of AF and CAD and the higher rates of cardiovascular events and death, our results indicate that apixaban may be a better treatment option than warfarin for these high-risk patients.
Source: International Journal of Cardiology - November 4, 2013 Category: Cardiology Authors: Maria Cecilia Bahit, Renato D. Lopes, Daniel M. Wojdyla, Stefan H. Hohnloser, John H. Alexander, Basil S. Lewis, Philip E. Aylward, Freek W.A. Verheugt, Matyas Keltai, Rafael Diaz, Michael Hanna, Christopher B. Granger, Lars Wallentin Tags: Original Articles Source Type: research
Are direct oral anticoagulants effective in reducing systemic embolism in patients with atrial fibrillation? A systematic review and meta-analysis of the literature
Atrial fibrillation (AF) is the most prevalent sustained heart arrhythmia. It is the most important clinical risk factor for systemic embolism (SE) and is regarded to be the cause of stroke in up to one fourth of cases [1]. However, since stroke is much more prevalent than SE in patients with AF, the latter is not considered to be a main single outcome parameter in AF trials. As a consequence, the majority of trials on the role of anticoagulants in AF patients have focused over stroke prevention, and SE has been included only as a part of composite end-points.
Source: International Journal of Cardiology - November 26, 2014 Category: Cardiology Authors: Nicola Mumoli, Marco Cei, Josè Vitale, Andrea Fontanella, Francesco Dentali Tags: Letters to the Editor Source Type: research
Antiplatelet Therapy in Japanese Patients with Atrial Fibrillation without Oral Anticoagulants: Pooled Analysis of Shinken Database, J-RHYTHM Registry and Fushimi AF Registry
Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke. Oral anticoagulants (OAC) are effective for stroke prevention in patients with AF, and recent evidences have revealed the efficacy and safety of non-vitamin K antagonist OAC (NOAC) as well as warfarin. Although aspirin was shown to be inferior to warfarin or apixaban in preventing stroke [1,2], it is still prescribed to many AF patients in clinical practice [3–5]. This may be because physicians perceived it to be a safer and more convenient alternative to OAC.
Source: International Journal of Cardiology - April 22, 2015 Category: Cardiology Authors: Hisashi Ogawa, Masaharu Akao, Shinya Suzuki, Takeshi Yamashita, Ken Okumura, Hirotsugu Atarashi, Hiroshi Inoue Tags: Letter to the Editor Source Type: research
Strokes after cardioversion of atrial fibrillation - the FibStroke study
Cardioversion of atrial fibrillation (AF) is associated with an increased risk for stroke. We identified all cardioversions during the 30days preceding stroke or transient ischemic attack (TIA) in patients with a previously diagnosed AF, and sought to assess the characteristics of cardioversions leading to stroke or TIA.
Source: International Journal of Cardiology - October 21, 2015 Category: Cardiology Authors: Antti Palomäki, Pirjo Mustonen, Juha E.K. Hartikainen, Ilpo Nuotio, Tuomas Kiviniemi, Antti Ylitalo, Päivi Hartikainen, Heidi Lehtola, Riho Luite, K.E. Juhani Airaksinen Tags: All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. Source Type: research
Strokes after cardioversion of atrial fibrillation — The FibStroke study
Cardioversion of atrial fibrillation (AF) is associated with an increased risk for stroke. We identified all cardioversions during the 30days preceding stroke or transient ischemic attack (TIA) in patients with a previously diagnosed AF, and sought to assess the characteristics of cardioversions leading to stroke or TIA.
Source: International Journal of Cardiology - October 21, 2015 Category: Cardiology Authors: Antti Palomäki, Pirjo Mustonen, Juha E.K. Hartikainen, Ilpo Nuotio, Tuomas Kiviniemi, Antti Ylitalo, Päivi Hartikainen, Heidi Lehtola, Riho Luite, K.E. Juhani Airaksinen Source Type: research
Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: Focus on apixaban
The high risk of both stroke and major bleeding in atrial fibrillation (AF) patients with chronic kidney disease (CKD) defines an important population for whom the assessment of the balance between the risk of ischemic stroke and of bleeding is essential. The use of novel oral anticoagulants (NOACs) may be a viable option in this population due to their greater net clinical benefit than warfarin, as demonstrated by the results of the clinical phase III trials. NOACs have been found to have a greater net clinical benefit than warfarin in patients at high risk of either stroke (CHADS2 ≥1 or CHA2DS2-VASc score≥2) or bleeding (HAS-BLED≥3).
Source: International Journal of Cardiology - September 30, 2016 Category: Cardiology Authors: Francesco Pelliccia, Salvatore Rosanio, Giuseppe Marazzi, Sara Poggi, Alessandra Tanzilli, Cesare Greco, Carlo Gaudio, Giuseppe Rosano Tags: Review Source Type: research
Optimizing bleeding risk assessment in patients with atrial fibrillation: To score or not to score?
Oral anticoagulant therapy (OAC) significantly reduces stroke and all-cause mortality in patients with atrial fibrillation (AF), but is often underused due to concerns about OAC-related bleeding [1]. Balancing the stroke and bleeding risks in AF patients sometimes may be challenging, especially in those with multiple risk factors, since AF-related stroke and OAC-related bleeding share many common risk factors, and the net clinical benefit from OAC is often even greater in high-risk patients compared with those perceived to be at low risk of bleeding [2].
Source: International Journal of Cardiology - January 29, 2018 Category: Cardiology Authors: Neboj ša Mujović, Tatjana S. Potpara Tags: Editorial Source Type: research
Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study
Atrial fibrillation is a common cause of stroke, and diabetes increases stroke risk. Stroke risk may vary depending on the type of diabetes. We investigated whether type 1 and type 2 diabetes are associated with different risks of thromboembolism among patients with atrial fibrillation.
Source: International Journal of Cardiology - July 22, 2018 Category: Cardiology Authors: Mia V. Fangel, Peter B. Nielsen, Torben B. Larsen, Bo Christensen, Thure F. Overvad, Gregory Y.H. Lip, Samuel Z. Goldhaber, Martin B. Jensen Source Type: research
Measuring apixaban levels in the elderly patient with non-valvular atrial fibrillation
Atrial fibrillation (AF) is the most common arrhythmia and its prevalence increases with age. As a result, elderly patients are at increased risk of AF-related stroke compared to younger patients [1]. It is estimated that AF accounts for 15% of all cases of ischemic stroke and 33% of stroke cases in the elderly [2].
Source: International Journal of Cardiology - April 8, 2021 Category: Cardiology Authors: Ran Nissan Tags: Editorial Source Type: research
Screening for atrial fibrillation: If I was left to my own devices
Atrial fibrillation (AF) is established as the most prevalent clinical arrhythmia, and a major risk factor for stroke, death, heart failure, cognitive decline, and hospitalisation [1]. Ranking these complications is difficult, however ischemic stroke caused by AF is posing a significant burden to patients, their next of kin, to physicians and to the health care system. The stroke risk in AF patients can be markedly lowered by oral anticoagulation (OAC) treatment [2], but many patients with AF have few or no symptoms [3], hence health care contacts and arrhythmia detection might be lacking [4].
Source: International Journal of Cardiology - November 16, 2021 Category: Cardiology Authors: Emma Svennberg, Johan Engdahl Tags: Editorial Source Type: research
Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis study
Conclusion: Rate of AF is moderate in asymptomatic AS. Longstanding but not episodic AF was, independently predictive of increased risk of heart failure and non-hemorrhagic stroke. New-onset AF was associated with cardiac decompensation.
Source: International Journal of Cardiology - October 13, 2011 Category: Cardiology Authors: Anders M. Greve, Eva Gerdts, Kurt Boman, Christa Gohlke-Baerwolf, Anne B. Rossebø, Christoph A. Nienaber, Simon Ray, Kenneth Egstrup, Terje R. Pedersen, Lars Køber, Ronnie Willenheimer, Kristian Wachtell Tags: Original Articles Source Type: research
Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: a meta-analysis
Conclusions: Persistent AF remains burdened from higher recurrence rates, however not so following redo-procedures. Three predictors, valvular AF, a left atrium diameter longer than 50mm and recurrence within 30days, could be appraised to drive selection of patients and therapeutic strategy.
Source: International Journal of Cardiology - May 24, 2012 Category: Cardiology Authors: F. D'Ascenzo, A. Corleto, G. Biondi-Zoccai, M. Anselmino, F. Ferraris, L. di Biase, A. Natale, R.J. Hunter, R.J. Schilling, S. Miyazaki, H. Tada, K. Aonuma, L. Yenn-Jiang, H. Tao, C. Ma, D. Packer, S. Hammill, F. Gaita Tags: Original Articles Source Type: research
Review of epidemiology and management of atrial fibrillation in developing countries
Conclusions: The limited studies available suggest that in the developing world there is a significant prevalence of AF, which is predominantly associated with hypertension and valvular heart disease, and carries a risk of stroke. Highly variable use of anticoagulants may be related to different health care and socioeconomic settings. More studies are needed to improve understanding of the epidemiology and management of AF in developing countries.
Source: International Journal of Cardiology - March 4, 2013 Category: Cardiology Authors: Tu N. Nguyen, Sarah N. Hilmer, Robert G. Cumming Tags: Reviews Source Type: research
Microparticles in atrial fibrillation: A link between cell activation or apoptosis, tissue remodelling and thrombogenicity
Abstract: Microparticles (MPs) are small membrane vesicles that are shed from virtually all cells in response to stress. Widely described in atherothrombotic diseases, recent data suggest a role for circulating MPs in the hypercoagulable state associated with supraventricular tachyarrhythmia. During atrial fibrillation, several mechanisms, such as high ventricular heart rate, low or oscillatory shear stress, stretch, hypoxia, inflammation and oxidative stress, are potent inducers of apoptotic cell death, which leads to the shedding of procoagulant MPs within the vasculature. As key regulators of cell–cell cross-talk and ...
Source: International Journal of Cardiology - April 26, 2013 Category: Cardiology Authors: L. Jesel, M. Abbas, F. Toti, A. Cohen, T. Arentz, O. Morel Tags: Reviews Source Type: research
Women hospitalized with atrial fibrillation: Gender differences, trends and outcome from a 20-year registry in a middle eastern country (1991–2010)
Conclusions: Women hospitalized with atrial fibrillation were older in age and had higher prevalence of co-morbid cardiovascular risk factors compared to men whereas, mortality and stroke rates were comparable.
Source: International Journal of Cardiology - November 19, 2012 Category: Cardiology Authors: Amar M. Salam, Hajar A. AlBinali, Abdul Wahid Al-Mulla, Nidal Asaad, Rajvir Singh, Awad Al-Qahtani, Jassim Al Suwaidi Tags: Original Articles Source Type: research
